Abstract
This study aimed at the preparation and characterization of preformed and in-situ formed liposomes for controlled delivery to the lungs. Two different liposome formulations were prepared and subjected to characterization of physical parameters (vesicle size, appearance, discharge rate, spray pattern and internal pressure) and drug release profile (% cumulative drug release and % drug retained). Formulations were then subjected to accelerated stability studies as per ICH guidelines. It was observed that vesicle size ranged between 2.35 ± 0.23 - 2.41± 0.3 μm and 1.22 ± 0.22- 1.34 ± 0.15 μm respectively for preformed and in-situ formed liposomes. The discharge rate and spray area were in ranges of 110 ± 2.4 -123 ± 2.6 & 115± 2.4 -127±2.3 mg/ actuation & 12.5 ±1.7 -14.1± 2.2 and 13.9 ± 2.1- 14.7± 2.0 cm2 respectively. In-situ liposomes showed better controlled release profile then preformed liposomes as it released 76.5± 2.4 - 58.5 ± 1.8 % drug in 12 hour while retaining 23.5 ± 1.9- 41.5 ± 1.6 % drug whereas preformed liposomes showed cumulative release of 66.5 ± 2.2- 84.5 ± 2.3 % and 15.5 ± 2.4- 33.5± 2.1 % fraction retained. Upon subjection to accelerated conditions for a period of 60 days, preformed liposome completely lost the objective of being controlled release formulation as they showed 92± 2.4 % cumulative release and only 08 ± 1.6 % fraction retained whereas in-situ formulation showed 62 ± 2.3 % cumulative release and 38 ± 2.1 % fraction retained.
Keywords: Tuberculosis, Alveoli, Liposome, Aerosol, Rifampicin, In-situ, Krebs-Henseleit Solution
Current Drug Delivery
Title: In-Situ Formation of Liposome of Rifampicin: Better Availability for Better Treatment
Volume: 6 Issue: 5
Author(s): Praveen Kumar Gaur, Shikha Mishra, V. B. Gupta, M. S. Rathod, Suresh Purohit and Bhavin A. Savla
Affiliation:
Keywords: Tuberculosis, Alveoli, Liposome, Aerosol, Rifampicin, In-situ, Krebs-Henseleit Solution
Abstract: This study aimed at the preparation and characterization of preformed and in-situ formed liposomes for controlled delivery to the lungs. Two different liposome formulations were prepared and subjected to characterization of physical parameters (vesicle size, appearance, discharge rate, spray pattern and internal pressure) and drug release profile (% cumulative drug release and % drug retained). Formulations were then subjected to accelerated stability studies as per ICH guidelines. It was observed that vesicle size ranged between 2.35 ± 0.23 - 2.41± 0.3 μm and 1.22 ± 0.22- 1.34 ± 0.15 μm respectively for preformed and in-situ formed liposomes. The discharge rate and spray area were in ranges of 110 ± 2.4 -123 ± 2.6 & 115± 2.4 -127±2.3 mg/ actuation & 12.5 ±1.7 -14.1± 2.2 and 13.9 ± 2.1- 14.7± 2.0 cm2 respectively. In-situ liposomes showed better controlled release profile then preformed liposomes as it released 76.5± 2.4 - 58.5 ± 1.8 % drug in 12 hour while retaining 23.5 ± 1.9- 41.5 ± 1.6 % drug whereas preformed liposomes showed cumulative release of 66.5 ± 2.2- 84.5 ± 2.3 % and 15.5 ± 2.4- 33.5± 2.1 % fraction retained. Upon subjection to accelerated conditions for a period of 60 days, preformed liposome completely lost the objective of being controlled release formulation as they showed 92± 2.4 % cumulative release and only 08 ± 1.6 % fraction retained whereas in-situ formulation showed 62 ± 2.3 % cumulative release and 38 ± 2.1 % fraction retained.
Export Options
About this article
Cite this article as:
Gaur Kumar Praveen, Mishra Shikha, Gupta B. V., Rathod S. M., Purohit Suresh and Savla A. Bhavin, In-Situ Formation of Liposome of Rifampicin: Better Availability for Better Treatment, Current Drug Delivery 2009; 6 (5) . https://dx.doi.org/10.2174/156720109789941623
DOI https://dx.doi.org/10.2174/156720109789941623 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |
Call for Papers in Thematic Issues
Advances of natural products, bio-actives and novel drug delivery system against emerging viral infections
Due to the increasing prevalence of viral infections and the ability of these human pathogens to develop resistance to current treatment strategies, there is a great need to find and develop new compounds to combat them. These molecules must have low toxicity, specific activity and high bioavailability. The most suitable ...read more
Electrospun Fibers as Drug Delivery Systems
In recent years, electrospun fibers have attracted considerable attention as potential platforms for drug delivery due to their distinctive properties and adaptability. These fibers feature a notable surface area-to-volume ratio and can be intentionally designed with high porosity, facilitating an increased capacity for drug loading and rendering them suitable for ...read more
Emerging Nanotherapeutics for Mitigation of Neurodegenerative Disorders
Conditions affecting the central nervous system (CNS) present a significant hurdle due to limited access of both treatments and diagnostic tools for the brain. The blood-brain barrier (BBB) acts as a barrier, restricting the passage of molecules from the bloodstream into the brain. The most formidable challenge facing scientists is ...read more
Nanotechnology Based Chemotherapy for the treatment of Head & Neck Cancer
The escalating recurrence rates observed in Head and Neck cancer, particularly within the chemo-therapeutically treated cohort (50-60%), can be attributed to the non-selective nature of current anticancer drug delivery modalities. In this context, nanotechnology-based drug delivery systems emerge as a promising avenue for achieving precise localization of therapeutic agents to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Oxidized Haemoglobin–Driven Endothelial Dysfunction and Immune Cell Activation: Novel Therapeutic Targets for Atherosclerosis
Current Medicinal Chemistry Nicotine Replacement Therapy During Pregnancy and Lactation Induce Structural and Functional Changes in the Lungs of the Progeny
Current Women`s Health Reviews Role of Statins in Peri-Operative Medicine
Current Drug Targets Clinical Applications of Nanotechnology in Atherosclerotic Diseases
Current Nanoscience Third and Fourth Generation Fluoroquinolone Antibacterials: A Systematic Review of Safety and Toxicity Profiles
Current Drug Safety Synthetic and Natural Protease Inhibitors Provide Insights into Parasite Development, Virulence and Pathogenesis
Current Medicinal Chemistry P2Y Purinoceptors as Potential Emerging Therapeutical Target in Vascular Disease
Current Pharmaceutical Design Ivabradine: Cardiovascular Effects
Recent Patents on Cardiovascular Drug Discovery The Extracellular Matrix of Blood Vessels
Current Pharmaceutical Design Haemostatic Activation in HIV Infected Patients Treated with Different Antiretroviral Regimens
Current HIV Research Atheroma Burden and Morphology in Women
Current Pharmaceutical Design Rheumatoid Arthritis: Cardiovascular Manifestations, Pathogenesis, and Therapy
Current Pharmaceutical Design Cardiac Mitochondrial Alterations Observed in Hyperglycaemic Rats - What Can We Learn From Cell Biology?
Current Diabetes Reviews Inflammatory Biomarkers in Peripheral Artery Disease: Diagnosis, Prognosis, and Therapeutic Challenges
Current Medicinal Chemistry Carbonyl-Scavenging Drugs & Protection Against Carbonyl Stress-Associated Cell Injury
Mini-Reviews in Medicinal Chemistry PET Imaging of the Peripheral Benzodiazepine Receptor: Monitoring Disease Progression and Therapy Response in Neurodegenerative Disorders
Current Pharmaceutical Design Impact of Novel Screening Technologies on Ion Channel Drug Discovery
Combinatorial Chemistry & High Throughput Screening Extra Virgin Olive Oil and Cardiovascular Diseases: Benefits for Human Health
Endocrine, Metabolic & Immune Disorders - Drug Targets Inhibition of sPLA2-IIA, C-reactive Protein or Complement: New Therapy for Patients with Acute Myocardial Infarction?
Cardiovascular & Hematological Disorders-Drug Targets Taking Risk Prediction to the Next Level. Advances in Biomarker Research for Atherosclerosis
Current Pharmaceutical Design